We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


24 August 2007 By Robert Cyran

With easy credit gone, megadeals are out why not turn to cash gushing, underleveraged drug companies? Rumoured deals for Bayer and Wyeth make a bit of sense, though a battle for the latter seems more plausible.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)